Literature DB >> 13439269

The arginase activity of erythrocytes and leukocytes with particular reference to pernicious anemia and thalassemia major.

J REYNOLDS, J H FOLLETTE, W N VALENTINE.   

Abstract

Entities:  

Keywords:  AMIDASES/in blood; ANEMIA, ERYTHROBLASTIC/blood in; ANEMIA, PERNICIOUS/blood in; ERYTHROCYTES/metabolism; LEUKOCYTES

Mesh：

Substances：

Year:  1957        PMID： 13439269

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN： 0022-2143


× No keyword cloud information.
  7 in total

1.  [Enzyme pathology of the blood cells].

Authors:  K U BLUM
Journal:  Blut       Date:  1962-06

2.  Hemolysis-associated pulmonary hypertension in thalassemia.

Authors:  Claudia R Morris; Frans A Kuypers; Gregory J Kato; Lisa Lavrisha; Sandra Larkin; Titi Singer; Elliott P Vichinsky
Journal:  Ann N Y Acad Sci       Date:  2005       Impact factor: 5.691

3.  Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease.

Authors:  Claudia R Morris; Gregory J Kato; Mirjana Poljakovic; Xunde Wang; William C Blackwelder; Vandana Sachdev; Stanley L Hazen; Elliott P Vichinsky; Sidney M Morris; Mark T Gladwin
Journal:  JAMA       Date:  2005-07-06       Impact factor: 56.272

4.  [Alteration of amino acid concentrations in plasma of ACD-blood during storage (author's transl)].

Authors:  N Liappis; H Beeser; P Bantzer
Journal:  Blut       Date:  1979-04-20

5.  Erythrocyte arginase activity as an indicator of lead exposure.

Authors:  K Fukumoto; I Karai; Y Nishikawa; S Horiguchi
Journal:  Br J Ind Med       Date:  1983-02

6.  Effect of experimental chronic renal failure upon the production of urea, as measured by the liver arginase activity in rats.

Authors:  A da Costa e Silva; Z P Albuquerque
Journal:  Experientia       Date:  1978-11-15

Review 7.  Nitric oxide and arginine dysregulation: a novel pathway to pulmonary hypertension in hemolytic disorders.

Authors:  Claudia R Morris; Mark T Gladwin; Gregory J Kato
Journal:  Curr Mol Med       Date:  2008-11       Impact factor: 2.222
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.